Care During Chemotherapy and Beyond
Generic name: Abiraterone acetate
Zytiga® is the trade name for the generic drug abiraterone acetate. In some cases, health care professionals may use the generic name
abiraterone acetate when referring to the trade name Zytiga®.
Zytiga® is a type of hormone therapy. This medication is classified as an “adrenal inhibitor". (For more detail, see “How Zytiga® Works” below)
What Zytiga Is Used For:
Zytiga® is indicated for use in combination with prednisone for the treatment of men with metastatic castration-resistant prostate
cancer who have already received prior chemotherapy containing docetaxel.
Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.
How Zytiga Is Given:
Zytiga® is a pill, taken by mouth. It is taken once a day.
It must be taken on an empty stomach (take the pill at least 2 hours after a meal,
and do not eat for at least 1 hour after taking the pill)
It should be taken at approximately the same time each day.
Prednisone [10mg daily] should be taken along with Zytiga®.
The amount of Zytiga® you receive depends on many factors. Your doctor will determine your dose and schedule
Important things to remember about the side effects of Zytiga®:
Most people will not experience all of the Zytiga® side effects listed.
Zytiga® side effects are often predictable in terms of their onset, duration, and severity.
Zytiga® side effects are almost always reversible and will go away after therapy is complete.
Zytiga® side effects may be quite manageable. There are many options to minimize or prevent the side effects of Zytiga®.
The following side effects are common (occurring in greater than 30%) for patients taking Zytiga®:
These side effects are less common (occurring in 10-29%) side effects for patients receiving Zytiga®:
Zytiga® works by inhibiting specific “enzymes” in your adrenal glands that are responsible for making androgens. For this reason, there is
an increased risk of over production of mineralcorticosteroids in your body while on Zytiga®. As a result, Zytiga® may cause hypertension
[high blood pressure], hypokalemia [low levels of potassium in the blood], and fluid retention. Because of this risk, Zytiga® should be
used cautiously in patients with a strong cardiovascular history, and patients should be monitored closely for these symptoms. Dosing along with prednisone
will decrease the risk of mineralocorticoid excess.
Not all side effects are listed above. Side effects that are very rare -- occurring in less than about 10 percent of patients -- are not listed here.
But you should always inform your health care provider if you experience any unusual symptoms.
When to contact your doctor or health care provider:
Contact your health care provider immediately, day or night, if you should experience any of the following symptoms:
Fever of 100.4° F (38° C or higher, chills)
Chest Pain or Irregular heart beats
Inability to urinate for 8 or more hours
Always inform your health care provider if you experience any unusual symptoms.
The following symptoms require medical attention, but are not an emergency. Contact your health care provider within 24 hours of noticing any
of the following:
Dizziness / Light headedness
Diarrhea (4-6 episodes in a 24-hour period)
Unusual bleeding or bruising
Black or tarry stools, or blood in your stools
Extreme fatigue (unable to carry on self-care activities)
Yellow coloring of your skin or eyes
Unusual elevation in blood pressure
Always inform your health care provider if you experience any unusual symptoms.
Before starting Zytiga® treatment, make sure you tell your doctor about any other medications you are taking (including
prescription, over-the-counter, vitamins, herbal remedies, etc.). Do not take aspirin, products containing aspirin unless your doctor specifically
Zytiga® is currently not indicated for use in women. However, if Zytiga® is given to a woman, getting pregnant should
be avoided and the woman should not breast feed.
Zytiga® is currently not indicated for use in women. Zytiga® should not be given to women who are pregnant or intend
to become pregnant. Pregnancy category X (Zytiga® may cause fetal harm when given to a pregnant woman. If a woman becomes pregnant
while taking Zytiga®, the medication must be stopped immediately and the woman given appropriate counseling).
It is not known if Zytiga® is excreted in semen, therefore, men should use a condom and another method of birth control during
treatment and for 1 week following the last dose of Zytiga®.
Zytiga® and prednisone are to be used together and neither medication should be interrupted or stopped unless your healthcare provider
tells you to. Take the medication exactly as directed.
Take at the same time each day
Take on an empty stomach
You will need to continue receiving your LHRH/GnRH agonists injections (ie Zoladex®, Lupron®, Trelstar®, etc) throughout treatment with Zytiga®.
If you are experiencing hot flashes, wear light clothing, stay in a cool environment to try and reduce symptoms. Consult your healthcare provider if
these worsen or become intolerable.
Get plenty of rest.
Maintain good nutrition.
If you experience symptoms or side effects, be sure to discuss them with your health care team. They can prescribe medications and/or offer other
suggestions that are effective in managing such problems.
Monitoring and Testing:
You will be checked regularly by your doctor while you are taking Zytiga®, to monitor side effects and check your response to therapy. Periodic blood work
will be obtained to monitor your complete blood count (CBC) as well as the function of other organs (such as your kidneys and liver), as deemed necessary
by your doctor.
How Zytiga Works:
Hormones are chemical substances that are produced by glands in the body, which enter the bloodstream and cause effects in other tissues. The use of
hormone therapy to treat cancer is based on the observation that receptors for specific hormones that are needed for cell growth are on the surface of some
tumor cells. Hormone therapy can work by stopping the production of a certain hormone, blocking hormone receptors or substituting chemically similar agents
for the active hormone, which cannot be used by the tumor cell. Different types of hormone therapies are categorized by their function and/or the type of
hormone that is affected.
The growth of prostate cancer is stimulated by male hormones (androgens / testosterone). Decreasing the production of these hormones is critical in helping
men fight prostate cancer. Androgens are primarily made by the testicles and adrenal glands. However, in men with advanced prostate cancer, the metastatic
tumors themselves have the capability to produce testosterone. Generally, prostate cancer responds to treatment that decreases androgen levels. Many
androgen deprivation therapies, decrease androgen production by the testicles but do not affect androgen production elsewhere in the body, such as the
adrenal glands or in the tumor.
Zytiga® works in a different manner than other androgen deprivation therapies. Zytiga® interferes with an enzyme that is
expressed in testicular, adrenal, and prostatic tumor tissues and is required as part of the body’s androgen producing process. Because of this
interference the amount of androgens produced are decreased. Zytiga®, blocks androgen production at three sources; the testes, the adrenal glands, as well
as from the tumor itself.
We strongly encourage you to talk with your health care professional about your specific medical condition and treatments. The information contained in
this website is meant to be helpful and educational, but is not a substitute for medical advice.
Chemocare.com is designed to provide the latest information about chemotherapy to patients and their families, caregivers and friends. For information about the 4th Angel Mentoring Program visit www.4thangel.org